Head-to-head comparison
| Property | Survodutide | Semaglutide |
|---|---|---|
| Category | Weight Loss | Weight Loss |
| Legal Status | Research Only | Prescription |
| Primary Route | subcutaneous | subcutaneous |
| Half-life | ~1 week (supports once-weekly dosing; Tmax ~51h in dogs, extended mean residence time) | ~7 days |
| Mol. Weight | — | 4,113.58 Da |
| Side Effects | Nausea, Vomiting, Diarrhea | Nausea (39%), Vomiting, Diarrhea |
Key differences
- Receptor targets: Survodutide is a dual GLP-1/glucagon receptor agonist; semaglutide is a GLP-1 receptor agonist only.
- Weight loss efficacy: Phase II data showed survodutide (4.8 mg) achieved approximately 18.7% weight loss at 46 weeks; semaglutide (2.4 mg) achieved 15–17% at 68 weeks in STEP trials.
- Liver fat: Survodutide has shown significant liver fat reduction in MASH trials; semaglutide also reduces liver fat but through GLP-1 mechanisms alone without glucagon-driven hepatic fat oxidation.
- Manufacturer: Survodutide is developed by Boehringer Ingelheim/Zealand Pharma; semaglutide by Novo Nordisk.
- Approval status: Semaglutide is FDA-approved for diabetes and obesity; survodutide is in Phase III trials.
- Energy expenditure: The glucagon component of survodutide increases resting energy expenditure; semaglutide primarily reduces caloric intake through appetite suppression without a direct energy expenditure effect.
- MASH indication: Survodutide is being specifically developed for MASH in addition to obesity; semaglutide's MASH data is secondary to its weight loss program.
The verdict
Survodutide's dual mechanism offers potential advantages over semaglutide, particularly for liver fat reduction and energy expenditure. Early trial data suggests competitive or superior weight loss. However, semaglutide is FDA-approved with extensive real-world data, while survodutide is still in Phase III. For patients with concurrent MASH and obesity, survodutide could eventually be the more targeted therapy. For general weight management today, semaglutide remains the proven standard.
Frequently asked questions
Phase II data suggests survodutide may produce slightly more weight loss than semaglutide (approximately 18.7% at 46 weeks vs 15–17% at 68 weeks), but different trial designs limit direct comparison. Phase III results will clarify the relative efficacy.
The glucagon receptor component increases resting energy expenditure and stimulates hepatic fat oxidation. This means survodutide addresses obesity from both sides: reducing intake (via GLP-1) and increasing expenditure (via glucagon). Semaglutide only addresses the intake side.
Survodutide is being specifically developed for MASH (metabolic dysfunction-associated steatohepatitis) and has shown significant liver fat reduction in trials. While semaglutide also reduces liver fat, survodutide's glucagon component provides a more direct hepatic mechanism.
Survodutide is in Phase III clinical trials for both obesity and MASH, developed by Boehringer Ingelheim. If trials succeed, FDA approval could follow, but no specific timeline is confirmed.
Both activate the GLP-1 receptor, so combining them would create redundant GLP-1 stimulation. Survodutide already includes GLP-1 agonism plus the added glucagon component, making it functionally a superset of semaglutide's mechanism.